Stratum Nutrition (a Novus International business), in collaboration with its commercialization partner, KitoZyme, has received regulatory approval from the Institutional Review Board for its clinical protocol, and it has initiated recruitment and randomization for an additional clinical study on the company’s branded chitin-glucan ingredient Artinia.
To build upon existing clinical evidence for this vegetarian fiber, Stratum has designed a randomized, double-blind, placebo-controlled, multi-centered clinical study to evaluate the effects of Artinia on the oxidation of low-density lipoprotein. In addition, this study will assess the effects of Artinia on other established biomarkers of glycemic control, inflammation and human safety.
Artinia is a chitin-glucan fiber derived from the mycelium of a non-genetically modified strain of Aspergillus niger, and features the benefits of both soluble and insoluble fibers. Initial study results are expected by the end of the year.
